105 related articles for article (PubMed ID: 28326835)
21. Expression status of CD44 and CD133 as a prognostic marker in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by radical esophagectomy.
Okamoto K; Ninomiya I; Ohbatake Y; Hirose A; Tsukada T; Nakanuma S; Sakai S; Kinoshita J; Makino I; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Miyashita T; Hidehiro T; Takamura H; Fushida S; Ohta T
Oncol Rep; 2016 Dec; 36(6):3333-3342. PubMed ID: 27748881
[TBL] [Abstract][Full Text] [Related]
22. Genetic variations in PRKAA1 predict the risk and progression of gastric Cancer.
Chen M; Jiang B; He B; Tang M; Wang P; Chen L; Lu J; Lu P
BMC Cancer; 2018 Sep; 18(1):923. PubMed ID: 30253744
[TBL] [Abstract][Full Text] [Related]
23. Role of CD44(high)/CD133(high) HCT-116 cells in the tumorigenesis of colon cancer.
Zhou JY; Chen M; Ma L; Wang X; Chen YG; Liu SL
Oncotarget; 2016 Feb; 7(7):7657-66. PubMed ID: 26840024
[TBL] [Abstract][Full Text] [Related]
24. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors.
Rocco A; Liguori E; Pirozzi G; Tirino V; Compare D; Franco R; Tatangelo F; Palaia R; D'Armiento FP; Pollastrone G; Affuso A; Bottazzi EC; Masone S; Persico G; Nardone G
J Cell Physiol; 2012 Jun; 227(6):2686-93. PubMed ID: 21898409
[TBL] [Abstract][Full Text] [Related]
25. ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α.
Lee JH; Hur W; Hong SW; Kim JH; Kim SM; Lee EB; Yoon SK
Oncol Rep; 2017 Feb; 37(2):813-822. PubMed ID: 27959451
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical expression of cancer stem cell related markers CD44 and CD133 in endometrial cancer.
Elbasateeny SS; Salem AA; Abdelsalam WA; Salem RA
Pathol Res Pract; 2016 Jan; 212(1):10-6. PubMed ID: 26608413
[TBL] [Abstract][Full Text] [Related]
27. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.
Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X
J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis.
Han Z; Chen Z; Zheng R; Cheng Z; Gong X; Wang D
World J Surg Oncol; 2015 Feb; 13():56. PubMed ID: 25889325
[TBL] [Abstract][Full Text] [Related]
29. Association of heparanase gene (HPSE-1) single nucleotide polymorphisms with gastric cancer.
Yue Z; Song Y; Wang Z; Luo Y; Jiang L; Xing L; Xu H; Zhang X
J Surg Oncol; 2010 Jul; 102(1):68-72. PubMed ID: 20578081
[TBL] [Abstract][Full Text] [Related]
30. Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer.
Aravantinos G; Isaakidou A; Karantanos T; Sioziou A; Theodoropoulos GE; Pektasides D; Gazouli M
Cancer Biomark; 2015; 15(6):843-50. PubMed ID: 26406410
[TBL] [Abstract][Full Text] [Related]
31. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of CD133 expression in gastric carcinoma.
Ishigami S; Ueno S; Arigami T; Uchikado Y; Setoyama T; Arima H; Kita Y; Kurahara H; Okumura H; Matsumoto M; Kijima Y; Natsugoe S
Anticancer Res; 2010 Jun; 30(6):2453-7. PubMed ID: 20651407
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
34. The promotion of nanoparticle delivery to two populations of gastric cancer stem cells by CD133 and CD44 antibodies.
Chen H; Lin J; Shan Y; Zhengmao L
Biomed Pharmacother; 2019 Jul; 115():108857. PubMed ID: 31048191
[TBL] [Abstract][Full Text] [Related]
35. DKK3 attenuates the cytotoxic effect of natural killer cells on CD133
Xia P; Xu XY
Mol Carcinog; 2017 Jul; 56(7):1712-1721. PubMed ID: 28218426
[TBL] [Abstract][Full Text] [Related]
36. Association of Two CD44 Polymorphisms with Clinical Outcomes of Gastric Cancer Patients.
Bitaraf SM; Mahmoudian RA; Abbaszadegan M; Mohseni Meybodi A; Taghehchian N; Mansouri A; Forghanifard MM; Memar B; Gholamin M
Asian Pac J Cancer Prev; 2018 May; 19(5):1313-1318. PubMed ID: 29802692
[TBL] [Abstract][Full Text] [Related]
37. Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer.
Ryu HS; Park DJ; Kim HH; Kim WH; Lee HS
Hum Pathol; 2012 Apr; 43(4):520-8. PubMed ID: 22018628
[TBL] [Abstract][Full Text] [Related]
38. Expression of CD133 as a cancer stem cell marker in invasive gastric carcinoma.
Attia S; Atwan N; Arafa M; Shahin RA
Pathologica; 2019 Mar; 111(1):18-23. PubMed ID: 31217618
[TBL] [Abstract][Full Text] [Related]
39. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
[TBL] [Abstract][Full Text] [Related]
40. Cancerous and non-neoplastic stem cells in the stomach similarly express CD44 and CD133.
Feitosa NPP; Pereira VBM; Silva BGB; Queroz AVF; Rodrigues BJ; Costa MLV; Alencar CH; Lima-Júnior RCP; Wong DVT; Frota CC; Almeida PRC
Acta Histochem; 2021 Oct; 123(7):151787. PubMed ID: 34517259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
